{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:56:17Z","timestamp":1791921377842,"version":"4.3.4"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["CRSII5_213514"],"award-info":[{"award-number":["CRSII5_213514"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["10000213"],"award-info":[{"award-number":["10000213"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["10001893"],"award-info":[{"award-number":["10001893"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["883582-ECOEVODRTB"],"award-info":[{"award-number":["883582-ECOEVODRTB"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Mycobacterium tuberculosis (Mtb) causes tuberculosis (TB) in humans. Poor treatment responses are a threat to global TB control, as such, understanding contributing factors to poor responses is important. We proposed that antibiotic tolerance could contribute to delayed culture conversion (recalcitrant TB), and resistance amplification in patients during TB treatment. We thus ventured to investigate the role of drug tolerance in delayed culture conversion and resistance amplification in TB patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected serial Mtb isolates from patients with (i) drug-susceptible TB who remained culture positive for up to 6\u2005years (i.e. recalcitrant TB), and (ii) multidrug-resistant TB (MDR-TB) where resistance amplified during treatment. We measured tolerance to rifampicin in drug-susceptible TB strains and tolerance to moxifloxacin in MDR-TB strains using a real-time time\u2013kill assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and discussion<\/jats:title>\n                    <jats:p>Rifampicin tolerance evolved within-host, increasing up to and \u223c1.5-fold, however, there was no apparent contribution of rifampicin tolerance to delayed culture conversion. Tolerance to moxifloxacin in MDR-TB patients appeared negatively associated with resistance amplification and consistently decreased over time in patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings confirm that antibiotic tolerance evolves in Mtb within patients over time during treatment. However, there was no evidence that this tolerance influences treatment responses, calling for further investigation of contributors to adverse treatment responses and their mitigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag007","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:33:48Z","timestamp":1768307628000},"source":"Crossref","is-referenced-by-count":3,"title":["Within-host evolution of drug tolerance in\n                    <i>Mycobacterium tuberculosis<\/i>"],"prefix":"10.1093","volume":"8","author":[{"given":"Valerie F A","family":"March","sequence":"first","affiliation":[{"name":"Department of Research, Swiss Tropical and Public Health Institute , Allschwil ,","place":["Switzerland"]},{"name":"University of Basel , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kakha","family":"Mchedlishvili","sequence":"additional","affiliation":[{"name":"Department of Research, Swiss Tropical and Public Health Institute , Allschwil ,","place":["Switzerland"]},{"name":"University of Basel , Basel ,","place":["Switzerland"]},{"name":"National Center for Tuberculosis and Lung Diseases (NCTLD) , Tbilisi ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galo A","family":"Goig","sequence":"additional","affiliation":[{"name":"Department of Research, Swiss Tropical and Public Health Institute , Allschwil ,","place":["Switzerland"]},{"name":"University of Basel , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Maghradze","sequence":"additional","affiliation":[{"name":"Department of Research, Swiss Tropical and Public Health Institute , Allschwil ,","place":["Switzerland"]},{"name":"University of Basel , Basel ,","place":["Switzerland"]},{"name":"National Center for Tuberculosis and Lung Diseases (NCTLD) , Tbilisi ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teona","family":"Avaliani","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases (NCTLD) , Tbilisi ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rusudan","family":"Aspindzelashvili","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases (NCTLD) , Tbilisi ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaza","family":"Avaliani","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases (NCTLD) , Tbilisi ,","place":["Georgia"]},{"name":"European University , Tbilisi ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Kipiani","sequence":"additional","affiliation":[{"name":"National Center for Tuberculosis and Lung Diseases (NCTLD) , Tbilisi ,","place":["Georgia"]},{"name":"David Tvildiani Medical University (DTMU) , Tbilisi ,","place":["Georgia"]},{"name":"The University of Georgia , Tbilisi ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-1204","authenticated-orcid":false,"given":"Nestani","family":"Tukvadze","sequence":"additional","affiliation":[{"name":"Department of Research, Swiss Tropical and Public Health Institute , Allschwil ,","place":["Switzerland"]},{"name":"University of Basel , Basel ,","place":["Switzerland"]},{"name":"National Center for Tuberculosis and Lung Diseases (NCTLD) , Tbilisi ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levan","family":"Jugheli","sequence":"additional","affiliation":[{"name":"Department of Research, Swiss Tropical and Public Health Institute , Allschwil ,","place":["Switzerland"]},{"name":"University of Basel , Basel ,","place":["Switzerland"]},{"name":"National Center for Tuberculosis and Lung Diseases (NCTLD) , Tbilisi ,","place":["Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Bouaouina","sequence":"additional","affiliation":[{"name":"Department of Research, Swiss Tropical and Public Health Institute , Allschwil ,","place":["Switzerland"]},{"name":"University of Basel , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Doetsch","sequence":"additional","affiliation":[{"name":"Department of Research, Swiss Tropical and Public Health Institute , Allschwil ,","place":["Switzerland"]},{"name":"University of Basel , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevda","family":"Kalkan","sequence":"additional","affiliation":[{"name":"Department of Research, Swiss Tropical and Public Health Institute , Allschwil ,","place":["Switzerland"]},{"name":"University of Basel , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Reinhard","sequence":"additional","affiliation":[{"name":"Department of Research, Swiss Tropical and Public Health Institute , Allschwil ,","place":["Switzerland"]},{"name":"University of Basel , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Gagneux","sequence":"additional","affiliation":[{"name":"Department of Research, Swiss Tropical and Public Health Institute , Allschwil ,","place":["Switzerland"]},{"name":"University of Basel , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Borrell","sequence":"additional","affiliation":[{"name":"Department of Research, Swiss Tropical and Public Health Institute , Allschwil ,","place":["Switzerland"]},{"name":"University of Basel , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"2026021005261117600_dlag007-B1","author":"WHO"},{"key":"2026021005261117600_dlag007-B2","doi-asserted-by":"publisher","first-page":"102511","DOI":"10.1016\/j.jiph.2024.102511","article-title":"Changes in the incidence, clinical features and outcomes of tuberculosis during COVID-19 pandemic","volume":"17","author":"Chan","year":"2024","journal-title":"J Infect Public Health"},{"key":"2026021005261117600_dlag007-B3","first-page":"163","volume-title":"Tuberculosis\u2014Current Issues in Diagnosis and Management","author":"Jnawali","year":"2013"},{"key":"2026021005261117600_dlag007-B4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40264-015-0267-y","article-title":"Safety and tolerability profile of second-line anti-tuberculosis medications","volume":"38","author":"Ramachandran","year":"2015","journal-title":"Drug Saf"},{"key":"2026021005261117600_dlag007-B5","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/S0140-6736(02)08830-X","article-title":"Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru","volume":"359","author":"Su\u00e1rez","year":"2002","journal-title":"Lancet"},{"key":"2026021005261117600_dlag007-B6","volume-title":"WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment-Drug-Resistant Tuberculosis Treatment, 2022 Update","author":"WHO","year":"2022"},{"key":"2026021005261117600_dlag007-B7","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"2026021005261117600_dlag007-B8","doi-asserted-by":"publisher","first-page":"1801528","DOI":"10.1183\/13993003.01528-2018","article-title":"High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen","volume":"52","author":"Ndjeka","year":"2018","journal-title":"Eur Respir J"},{"key":"2026021005261117600_dlag007-B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2404644","volume":"392","author":"Goig","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021005261117600_dlag007-B10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s13104-018-3473-8","article-title":"Analysis of tuberculosis treatment outcomes among pulmonary tuberculosis patients in Bahawalpur, Pakistan","volume":"11","author":"Atif","year":"2018","journal-title":"BMC Res Notes"},{"key":"2026021005261117600_dlag007-B11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.amsu.2020.11.032","article-title":"Impact of HIV status and predictors of successful treatment outcomes among tuberculosis patients: a six-year retrospective cohort study","volume":"60","author":"Fekadu","year":"2020","journal-title":"Ann Med Surg (Lond)"},{"key":"2026021005261117600_dlag007-B12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.5588\/pha.16.0107","article-title":"Tuberculosis treatment outcomes among disadvantaged patients in India","volume":"7","author":"Jackson","year":"2017","journal-title":"Public Health Action"},{"key":"2026021005261117600_dlag007-B13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5588\/pha.14.0042","article-title":"Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus","volume":"4","author":"Khaliaukin","year":"2014","journal-title":"Public Health Action"},{"key":"2026021005261117600_dlag007-B14","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/ijerph182010678","article-title":"Factors associated with poor tuberculosis treatment outcome in the southern region of Ethiopia","volume":"14","author":"Mu\u00f1oz-Sellart","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026021005261117600_dlag007-B15","doi-asserted-by":"publisher","first-page":"10678","DOI":"10.3390\/ijerph182010678","article-title":"Tuberculosis treatment outcome and predictors in Africa: a systematic review and meta-analysis","volume":"18","author":"Teferi","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2026021005261117600_dlag007-B16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/1471-2458-7-291","article-title":"Risk factors for poor tuberculosis treatment outcome in Finland: a cohort study","volume":"7","author":"Vasankari","year":"2007","journal-title":"BMC Public Health"},{"key":"2026021005261117600_dlag007-B17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ijid.2020.05.087","article-title":"Poor treatment outcome and its predictors among drug-resistant tuberculosis patients in Ethiopia: a systematic review and meta-analysis","volume":"98","author":"Alemu","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2026021005261117600_dlag007-B18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5588\/pha.16.0055","article-title":"Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India","volume":"7","author":"Nair","year":"2017","journal-title":"Public Health Action"},{"key":"2026021005261117600_dlag007-B19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12879-018-3019-7","article-title":"Treatment outcomes and factors affecting unsuccessful outcome among new pulmonary smear positive and negative tuberculosis patients in Anqing, China: a retrospective study","volume":"18","author":"Wen","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2026021005261117600_dlag007-B20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12879-016-1534-y","article-title":"Poor tuberculosis treatment outcomes in Southern Mozambique (2011\u20132012)","volume":"16","author":"Garc\u00eda-Basteiro","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2026021005261117600_dlag007-B21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1258\/td.2011.110421","article-title":"Treatment outcome of HIV-associated tuberculosis in a resource-poor setting","volume":"42","author":"Ifebunandu","year":"2012","journal-title":"Trop Doct"},{"key":"2026021005261117600_dlag007-B22","doi-asserted-by":"publisher","first-page":"e82943","DOI":"10.1371\/journal.pone.0082943","article-title":"Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation","volume":"8","author":"Tang","year":"2013","journal-title":"PLoS One"},{"key":"2026021005261117600_dlag007-B23","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.cmi.2017.09.012","article-title":"Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study","volume":"24","author":"Javaid","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2026021005261117600_dlag007-B24","doi-asserted-by":"publisher","first-page":"e6914","DOI":"10.1371\/journal.pone.0006914","article-title":"Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"4","author":"Johnston","year":"2009","journal-title":"PLoS ONE"},{"key":"2026021005261117600_dlag007-B25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13073-025-01555-0","article-title":"Clinical and bacterial determinants of unfavorable tuberculosis treatment outcomes: an observational study in Georgia","volume":"17","author":"Goig","year":"2025","journal-title":"Genome Med"},{"key":"2026021005261117600_dlag007-B26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrmicro.2016.34","article-title":"Distinguishing between resistance, tolerance and persistence to antibiotic treatment","volume":"14","author":"Brauner","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"2026021005261117600_dlag007-B27","doi-asserted-by":"publisher","first-page":"e0010624","DOI":"10.1128\/cmr.00106-24","article-title":"Antibiotic tolerance among clinical isolates: mechanisms, detection, prevalence, and significance","volume":"37","author":"Deventer Ashley","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"2026021005261117600_dlag007-B28","doi-asserted-by":"publisher","first-page":"e03482-20","DOI":"10.1128\/mBio.03482-20","article-title":"Evolution of antibiotic tolerance shapes resistance development in chronic Pseudomonas aeruginosa infections","volume":"12","author":"Santi","year":"2021","journal-title":"MBio"},{"key":"2026021005261117600_dlag007-B29","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1126\/science.aaj2191","article-title":"Antibiotic tolerance facilitates the evolution of resistance","volume":"355","author":"Levin-Reisman","year":"2017","journal-title":"Science"},{"key":"2026021005261117600_dlag007-B30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1126\/science.aay3041","article-title":"Effect of tolerance on the evolution of antibiotic resistance under drug combinations","volume":"367","author":"Liu","year":"2020","journal-title":"Science"},{"key":"2026021005261117600_dlag007-B31","doi-asserted-by":"publisher","first-page":"e0099625","DOI":"10.1128\/aac.00996-25","article-title":"Variability in intrinsic drug tolerance in Mycobacterium tuberculosis corresponds with phylogenetic lineage","volume":"69","author":"March","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021005261117600_dlag007-B32","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1128\/JCM.02993-14","article-title":"Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases","volume":"53","author":"Witney","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2026021005261117600_dlag007-B33","doi-asserted-by":"publisher","first-page":"100936","DOI":"10.1016\/j.lanmic.2024.06.003","article-title":"Signatures of transmission in within-host Mycobacterium tuberculosis complex variation: a retrospective genomic epidemiology study","volume":"6","author":"Walter","year":"2025","journal-title":"Lancet Microbe"},{"key":"2026021005261117600_dlag007-B34","doi-asserted-by":"publisher","first-page":"eaba4901","DOI":"10.1126\/sciadv.aba4901","article-title":"Mycobacterium tuberculosis clinical isolates carry mutational signatures of host immune environments","volume":"6","author":"Liu","year":"2020","journal-title":"Sci Adv"},{"key":"2026021005261117600_dlag007-B35","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-021-01358-x","article-title":"Prisons as ecological drivers of fitness-compensated multidrug-resistant Mycobacterium tuberculosis","volume":"27","author":"Gygli","year":"2021","journal-title":"Nat Med"},{"key":"2026021005261117600_dlag007-B36","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/s41467-023-37719-y","article-title":"The relative transmission fitness of multidrug-resistant Mycobacterium tuberculosis in a drug resistance hotspot","volume":"14","author":"Loiseau","year":"2023","journal-title":"Nat Commun"},{"key":"2026021005261117600_dlag007-B37","doi-asserted-by":"publisher","first-page":"e01439-20","DOI":"10.1128\/AAC.01439-20","article-title":"Most-probable-number-based minimum duration of killing assay for determining the spectrum of rifampicin susceptibility in clinical Mycobacterium tuberculosis isolates","volume":"65","author":"Vijay","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026021005261117600_dlag007-B38","doi-asserted-by":"publisher","first-page":"RP93243","DOI":"10.7554\/eLife.93243","article-title":"Rifampicin tolerance and growth fitness among isoniazid-resistant clinical Mycobacterium tuberculosis isolates: an in-vitro longitudinal study","volume":"13","author":"Srinivasan","year":"2024","journal-title":"eLife"},{"key":"2026021005261117600_dlag007-B39","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026021005261117600_dlag007-B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CPAA.S289714","article-title":"The impact of first-line anti-tubercular drugs\u2019 pharmacokinetics on treatment outcome: a systematic review","volume":"13","author":"Sileshi","year":"2021","journal-title":"Clin Pharmacol"},{"key":"2026021005261117600_dlag007-B41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cid\/cis353","article-title":"Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy","volume":"55","author":"Pasipanodya","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026021005261117600_dlag007-B42","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1093\/cid\/ciz942","article-title":"Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis","volume":"70","author":"Alffenaar","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026021005261117600_dlag007-B43","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1371\/journal.pmed.0040238","article-title":"Patient adherence to tuberculosis treatment: a systematic review of qualitative research","volume":"4","author":"Munro","year":"2007","journal-title":"PLoS Med"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/1\/dlag007\/66839413\/dlag007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/1\/dlag007\/66839413\/dlag007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T10:26:20Z","timestamp":1770719180000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag007\/8471061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag007","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,7]]},"article-number":"dlag007"}}